Mylan N.V. (MYL) Upgraded by BidaskClub to “Hold”
BidaskClub upgraded shares of Mylan N.V. (NASDAQ:MYL) from a sell rating to a hold rating in a research note released on Tuesday.
Several other research firms have also recently issued reports on MYL. UBS AG reissued a buy rating and issued a $46.00 price objective (down from $50.00) on shares of Mylan N.V. in a research report on Thursday, August 10th. Citigroup Inc. raised shares of Mylan N.V. from a neutral rating to a buy rating and raised their target price for the stock from $36.00 to $42.00 in a research report on Wednesday, August 16th. Mizuho reaffirmed a buy rating and set a $37.00 price target (down previously from $53.00) on shares of Mylan N.V. in a research note on Sunday, August 20th. BMO Capital Markets reaffirmed a buy rating and set a $45.00 price target on shares of Mylan N.V. in a research note on Friday, September 29th. Finally, ValuEngine raised shares of Mylan N.V. from a hold rating to a buy rating in a research note on Monday. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $41.87.
Shares of Mylan N.V. (NASDAQ:MYL) traded up 18.17% during mid-day trading on Tuesday, reaching $38.44. 10,941,945 shares of the company’s stock traded hands. Mylan N.V. has a 12-month low of $29.39 and a 12-month high of $45.87. The firm has a market capitalization of $20.61 billion, a price-to-earnings ratio of 31.08 and a beta of 1.30. The stock has a 50-day moving average price of $31.43 and a 200 day moving average price of $36.46.
Mylan N.V. (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company’s quarterly revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.16 EPS. Analysts anticipate that Mylan N.V. will post $4.52 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of MYL. Wellington Management Group LLP grew its holdings in Mylan N.V. by 2.6% in the first quarter. Wellington Management Group LLP now owns 46,373,108 shares of the company’s stock worth $1,808,088,000 after purchasing an additional 1,165,852 shares during the last quarter. BlackRock Inc. increased its position in shares of Mylan N.V. by 4.5% during the second quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock worth $1,575,089,000 after purchasing an additional 1,751,515 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Mylan N.V. by 12.0% during the second quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock worth $1,276,432,000 after purchasing an additional 3,531,974 shares in the last quarter. State Street Corp increased its position in shares of Mylan N.V. by 1.6% during the second quarter. State Street Corp now owns 20,498,541 shares of the company’s stock worth $795,751,000 after purchasing an additional 321,977 shares in the last quarter. Finally, Pzena Investment Management LLC increased its position in shares of Mylan N.V. by 69.9% during the second quarter. Pzena Investment Management LLC now owns 12,339,687 shares of the company’s stock worth $479,027,000 after purchasing an additional 5,077,371 shares in the last quarter. 71.97% of the stock is owned by institutional investors.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.